title: [Loco-regional cancer chemotherapy in patients with malignant pleural effusion--improving the QOL of patients].
abstract: We carried out a new loco-regional cancer chemotherapy for serious patients with malignant pleural effusion, in an attempt to prevent the recurrence of effusion. After removing pleural effusion, fibrinogen solution, anticancer agent and our newly devised compound drug, "G.T.XIII" were intrapleurally instilled to enhance an anticancer fibrin membrane. This pleurodesis was called "Bio-Adhesio-Chemo (BAC) therapy". Some 39 BAC therapies were carried out for 34 patients. There were 32 cases evaluable; 29 resulted in PR, and three were NC. Improvement of P.S. was observed in 77% (30/39). Aggravation of P.S. was nil. Sixteen patients were discharged after showing favorable improvement. Toxic effects with the therapy were rather mild. Such results were attributed to the biomechanism of both the adhesive and oncolytic effects of the fibrin membrane enhanced with BAC therapy. Immunological studies suggested that the fibrin membrane also worked as BRM in the pleural cavity. Our own BAC therapy showed a great potential in improving the QOL of patients with malignant pleural effusion.
authors.affiliation: Dept. of Surgery, Osaka National Hospital, Japan.
authors.forename: A
authors.initials: A
authors.lastname: Sugitachi
authors.forename: T
authors.initials: T
authors.lastname: Kawahara
authors.forename: T
authors.initials: T
authors.lastname: Kido
authors.forename: T
authors.initials: T
authors.lastname: Shindoh
authors.forename: I
authors.initials: I
authors.lastname: Sakamoto
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage* / Q000009:adverse effects; D003692:Delayed-Action Preparations; D004317:Doxorubicin / Q000008:administration & dosage* / Q000009:adverse effects; D004341:Drug Evaluation; D005176:Factor XIII; D005260:Female; D005334:Fever / Q000139:chemically induced; D005340:Fibrinogen; D006801:Humans; D007263:Infusions, Parenteral; D008175:Lung Neoplasms / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D010996:Pleural Effusion / Q000188:drug therapy* / Q000517:prevention & control; D010997:Pleural Neoplasms / Q000188:drug therapy; D011788:Quality of Life; D013917:Thrombin; D014839:Vomiting / Q000139:chemically induced
chemical_list: D003692:Delayed-Action Preparations; D004317:Doxorubicin; D005340:Fibrinogen; D005176:Factor XIII; D013917:Thrombin; D002945:Cisplatin